Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%
07 juin 2024 03h38 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033" report has been added to ResearchAndMarkets.com's offering. The 2023-2033 Fiber...
Revenue Cycle Management Market Size to Hit USD 343.12 Bn by 2031
05 juin 2024 07h23 HE
|
CMI
Burlingame, June 05, 2024 (GLOBE NEWSWIRE) -- The global revenue cycle management market is estimated to be valued at USD 156.68 Bn in 2024 and is expected to reach USD 343.12 Bn by 2031, exhibiting...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
05 juin 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
ChainGPT Pad launches $COOKIE to introduce ‘MarketingFi,’ a transparent, decentralized, and user-centric approach to marketing
04 juin 2024 09h28 HE
|
ChainGPT
Dover, DE, June 04, 2024 (GLOBE NEWSWIRE) -- ChainGPT, the AI-powered Web3 infrastructure providing a diverse suite of tools and services, exclusively launches the latest IDO - $COOKIE. Through a...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01 juin 2024 08h00 HE
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31 mai 2024 16h05 HE
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
Immuron CEO Steven Lydeamore to present at Peak Sky High
31 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief...
Immuron Board Changes
31 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston...
Galapagos en Adaptimmune ondertekenen klinische samenwerkingsovereenkomst met optie om Adaptimmune's TCR T-celtherapiekandidaat, uza-cel, exclusief in te licentiëren voor hoofd- & halskanker en mogelijke toekomstige vaste tumoren indicaties
30 mai 2024 16h01 HE
|
Galapagos NV
Adaptimmune en Galapagos zullen een klinische proof-of-concept studie uitvoeren om de veiligheid en werkzaamheid te evalueren van uza-cel (nieuwe generatie MAGE-A4 TCR T-celtherapie) geproduceerd op...
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
30 mai 2024 16h01 HE
|
Galapagos NV
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized...